Kerry Wentworth, serving as Chief Regulatory Officer at Nuvation Bio Inc. (NASDAQ:NUVB), completed a transaction involving the sale of 63,000 shares of Class A Common Stock on June 23, 2026. According to a recent SEC Form 4 filing, the total proceeds from this divestment amounted to $379,190. The transaction was executed at a weighted-average price of $6.0189 per share, with the final price falling within a narrow band between $6.00 and $6.08. This sale was conducted under the parameters of a 10b5-1 trading plan, which was originally established on December 4, 2025.
Key Points
- Insider Activity: Kerry Wentworth sold 63,000 shares via a 10b5-1 plan, following the exercise of options acquired at $2.93 per share. Post-transaction, she retains direct ownership of 53,000 shares.
- Financial Performance: Nuvation Bio reported first-quarter 2026 revenue of $83.2 million, surpassing the $66.2 million forecast by 25.69%. Earnings per share stood at $0.01, in line with analyst expectations.
- Market Context: The company’s stock has surged 215% over the past year, currently trading at $6.46 with a market capitalization of $2.25 billion. RBC Capital maintains an Outperform rating with a $20.00 price target, citing strategic industry dynamics.
The transaction occurred against a backdrop of significant corporate developments. Nuvation Bio reported first-quarter 2026 earnings that demonstrated robust financial health, with revenue significantly exceeding forecasts. The company achieved earnings per share of $0.01, aligning with analysts’ expectations, while revenue reached $83.2 million, surpassing the predicted $66.2 million by 25.69%. Additionally, RBC Capital reiterated an Outperform rating for Nuvation Bio, maintaining a price target of $20.00. This analyst stance follows GSK’s proposed $10.6 billion acquisition of Nuvularia, a competitor in the ROS1 market. GSK attributed up to $3.5 billion of the deal to this asset, highlighting the continued value seen in the ROS1 space.
Furthermore, Nuvation Bio released patient-reported outcomes data from the TRUST-II study of IBTROZI at the American Society of Clinical Oncology Annual Meeting. The data showed that 88% of patients reported improved or stable global health quality-of-life scores. In another development, Nuvation Bio completed a process technology transfer and product introduction to Thermo Fisher Scientific for manufacturing IBTROZI in the United States. This transition was submitted as a supplement to the IBTROZI New Drug Application. These recent developments reflect Nuvation Bio’s ongoing activities in the pharmaceutical sector.
Risks and Uncertainties
- Valuation Concerns: InvestingPro analysis suggests the stock may be overvalued at current levels relative to its Fair Value estimate, despite the recent surge and strong earnings.
- Regulatory and Operational Dependencies: The company relies on external partners like Thermo Fisher Scientific for manufacturing, and success depends on the approval and execution of supplements to the IBTROZI New Drug Application.
- Market Volatility: The 215% stock surge over the past year presents potential volatility risks, as the stock trades at $6.46 with a market capitalization of $2.25 billion, requiring careful monitoring of valuation metrics.
For investors seeking deeper insights, InvestingPro offers exclusive access to comprehensive Pro Research Reports covering NUVB and 1,400+ other US equities. The fastest way to find out if NUVB is a bargain right now is through their Fair Value calculator, which uses a mix of 17 proven industry valuation models for maximum accuracy. This tool helps provide the bottom line for NUVB plus thousands of other stocks to find hidden gems with massive upside.